Abstract：
Treatment options are currently limited for persons with HIV-1 (PWH) who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. In addition, future areas of research are also identified and discussed.
摘要：
目前，对于具有大量治疗经验和/或具有多重耐药性HIV-1的HIV-1（PWH）患者，治疗选择有限。自2018年以来，美国食品和药物管理局（FDA）批准了三种药物，这代表了该人群的显着进步：ibalizumab，festemsavir,还有Lenacapavir.然而,缺乏描述最佳使用的国家和国际准则认可的建议(例如，开始后的选择和监测）在该人群中使用这些新型抗逆转录病毒药物。为了解决这个差距，使用改良的Delphi技术来制定这些共识建议，以建立启动和管理ibalizumab的框架，festemsavir,或PWH中的lenacapavir，具有大量治疗经验和/或具有多重耐药性HIV-1。此外,还确定和讨论了未来的研究领域。
